Product Description
Bevenopran has been used in trials studying the treatment of Renal Impairment and Opioid-Induced Constipation. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bevenopran)
Mechanisms of Action: OPRM Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Constipation
Phase 1: Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 5945-SOIC-12-05 | P3 |
Terminated |
Constipation |
2014-07-21 |
|
| 5945-OIC-12-03 | P3 |
Terminated |
Constipation |
2014-02-13 |
|
| 5945-OIC-12-02 | P3 |
Terminated |
Constipation |
2014-02-13 |
|
| 5945-OIC-12-04 | P3 |
Terminated |
Constipation |
2014-02-13 |
|
| 5945-REN-13-03 | P1 |
Terminated |
Kidney Diseases |
2013-12-01 |
|
| 45CL243 | P2 |
Completed |
Constipation |
2011-07-15 |
|
| 45CL242 | P2 |
Completed |
Constipation |
2011-04-18 |